Home › Diffuse Scleroderma › Pennsylvania
Diffuse Scleroderma clinical trials in Pennsylvania
6 studies for Diffuse Scleroderma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- EncompaSSc site in Philadelphia, PA, Philadelphia
- EncompaSSc site in Pittsburgh, PA, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07287670A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717Platform Clinical Study for Conquering Scleroderma
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 2
Ages 8 to 60 · All sexes · Updated Aug 14, 2026 · NCT03630211The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
- University of Pittsburgh and UPMC Scleroderma Center, Pittsburgh
Recruiting
Ages 18 and older · All sexes · Updated Jan 8, 2026 · NCT06675344From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.